Health2Sync announced today that the partnership with Sanofi has extended its footprints to South Korea, along with the launch of SoloSmart™, an integrated digital solution developed by Sanofi to help facilitate personalized care for patients with diabetes. This partnership marks a milestone for the first data integration of SoloSmart™ with a single chronic disease management App in Korea. It brings forth the fourth country in which the two companies collaborated, namely Taiwan, Japan, Egypt, and now Korea.

To provide comprehensive daily diabetes management and a better user experience, Health2Sync recently included Korean in its well-recognized patient app and the “Patient Management Platform.” Patients with diabetes can easily record their blood glucose, diet, exercise, and medications on "슈가 지니/SugarGenie" as well as the insulin information with the help of SoloSmart™, the connected insulin pen cap to be attached to Sanofi’s insulin pen SoloStar®.
 
Once the patient injects insulin, accurate details such as the date, time, and dose of the insulin injection are automatically captured and recorded by SoloSmart™, then transmitted in real-time to “슈가지니/SugarGenie“ and the Health2Sync platform, assisting the physicians and care providers in tracking patients' vitals and getting insights to understand progress. SoloSmart™ is expected to improve adherence to insulin therapy by preventing dose missing through timely titration alerts. In fact, according to a Taiwanese study, the use of the insulin pen connection cap increased insulin dosage by 17.6%, and glycated hemoglobin significantly decreased by 2.4% and 0.5% in both new and existing patients receiving Toujeo (p<0.05).
 
"We find it very meaningful that we could bring SoloSmart™ and 슈가지니/SugarGenie, a mobile App we developed for Korea, through our partnership with Sanofi,” said Ed Deng, Co-founder & CEO of Health2Sync. “We hope that SoloSmart™ and SugarGenie will contribute to reducing patients’ burdens in their daily diabetes management, ultimately improving outcomes and reducing healthcare expenses by providing an effective and scalable digital solution.”
 
The Health2Sync app has 1.3 million registered users worldwide as of August 2024, and the company is looking forward to creating a real-time monitoring ecosystem in diabetes management by leveraging various devices, including continuous glucose monitoring (CGM), blood glucose meters (BGM), exercise and sleep trackers, and smartwatches such as Fitbit.
 
About Health2Sync
Founded in 2013, Health2Sync offers digital solutions to help people with chronic diseases, pre-diabetes, or weight concerns to manage their health. The company's achievements include being the first approved digital therapeutics in Taiwan for their insulin dosage titration software, Insultrate, which they co-developed with Sanofi. The company has also received the "NEXT BIG" Startup title by the Taiwan National Development Council.
 
For more information, please visit https://www.health2sync.com.